Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19259859 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | July 2025 | February 2026 | Abandon | 7 | 1 | 0 | No | No |
| 18736487 | CARDIOPULMONARY PROGENITOR EXOSOMES, PREPARATION METHOD AND APPLICATION THEREOF | June 2024 | December 2025 | Abandon | 18 | 3 | 1 | No | No |
| 18668297 | Cell Growth Promoter and Application thereof | May 2024 | October 2025 | Allow | 17 | 3 | 1 | Yes | No |
| 18629638 | PLATELET DIAGNOSTIC IMAGING AGENTS | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18627513 | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response | April 2024 | December 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18288332 | METHOD FOR ENRICHING CELLS OR CELL NUCLEI | October 2023 | May 2025 | Abandon | 18 | 2 | 1 | Yes | No |
| 18359240 | Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In Bioreactors | July 2023 | April 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18345212 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF | June 2023 | March 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18213593 | METHOD FOR PROMOTING AND IMPROVING PROPERTIES OF ADIPOSE TISSUE, TISSUE AND CELLS OBTAINED BY SAID METHOD | June 2023 | March 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18301864 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN CANINES AND IMPROVED CELL CULTIVATION METHODS | April 2023 | January 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18301856 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN EQUINES AND IMPROVED CELL CULTIVATION METHODS | April 2023 | January 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18194313 | LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION | March 2023 | February 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18152249 | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues | January 2023 | January 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18061359 | CANINE BLOOD PLATELET PREPARATIONS | December 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17926268 | CALCINEURIN INHIBITOR TO IMPROVE CD3+CELL SURVIVAL TO THEREBY FACILITATE ENGRAFTMENT OF DONOR CD34+ CELLS IN A RECIPIENT | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17985641 | METHODS AND PRODUCTION OF NOVEL PLATELETS | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17998228 | ARTIFICIAL ANTIGEN PRESENTING CELL SYSTEM AND USES THEREOF | November 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17956347 | Modulation of Microglia Activation | September 2022 | March 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17911237 | Hepatic Stem-Like Cells for the Treatment and/or the Prevention of Liver Disorders | September 2022 | February 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17888245 | METHOD FOR CULTIVATING STEM CELLS IN VITRO | August 2022 | May 2025 | Allow | 33 | 2 | 1 | Yes | Yes |
| 17859452 | BONE REPAIR COMPOSITIONS | July 2022 | March 2025 | Abandon | 32 | 3 | 1 | No | No |
| 17827077 | A METHOD FOR TREATING MULTIPLE SCLEROSIS WITH PEPTIDE-LOADED DENDRITIC CELLS | May 2022 | April 2024 | Allow | 23 | 6 | 0 | No | No |
| 17825366 | METHOD OF PRODUCING SKIN-DERIVED PRECURSOR CELLS | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17756304 | Method And System For Identifying And Validating Shared Candidate Antigens And Shared Antigen-Specific T Lymphocyte Pairs | May 2022 | October 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17662704 | STEM CELL LINE FOR TREATMENT OF VARIOUS MEDICAL CONDITIONS | May 2022 | April 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17731295 | ALTERNATING TANGENTIAL FLOW RAPID HARVESTING | April 2022 | October 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17726902 | REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES | April 2022 | December 2024 | Abandon | 31 | 4 | 1 | Yes | Yes |
| 17711720 | QUADRI-POSITIVE STROMAL CELL (QPSC) POPULATION FOR SUPERIOR CELL PROTECTION AND IMMUNOMODULATION | April 2022 | May 2025 | Abandon | 38 | 2 | 1 | Yes | No |
| 17687478 | THERAPEUTIC MONOCYTES FOR PREVENTION OF SUICIDAL IDEATION | March 2022 | January 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17667434 | METHODS FOR STORAGE OF STEM CELLS | February 2022 | October 2025 | Abandon | 44 | 5 | 1 | No | No |
| 17579153 | Use of Adipose-Derived Stem Cells for Glaucoma Treatment | January 2022 | August 2025 | Abandon | 43 | 4 | 1 | Yes | No |
| 17622190 | MODULATION OF T CELL CYTOTOXICITY AND RELATED THERAPY | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17620565 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17617495 | 3D Bioprinted Skin Tissue Model | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17615679 | BONE MARROW MICROGLIA PROGENITOR CELLS AND USES THEREOF | December 2021 | November 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17527503 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | January 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17527510 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17527512 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17527498 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | December 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17527489 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17527494 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17527516 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17527505 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | May 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17527523 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | December 2025 | Abandon | 49 | 5 | 1 | No | No |
| 17527527 | METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE | November 2021 | February 2026 | Abandon | 51 | 5 | 0 | Yes | No |
| 17454586 | PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF | November 2021 | April 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17499809 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF | October 2021 | August 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17498683 | MESENCHYMAL STEM CELLS FOR ORAL INFLAMMATION TREATMENT | October 2021 | December 2024 | Abandon | 38 | 2 | 0 | No | Yes |
| 17497779 | USES OF MESENCHYMAL STEM CELLS | October 2021 | May 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17403202 | GENERATING VASCULOGENIC CELL POPULATIONS | August 2021 | May 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17387548 | COMBINATORIAL CULTURE CONDITION ARRAYS AND USES THEREOF | July 2021 | December 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17305483 | METHODS OF TREATMENT USING PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS | July 2021 | October 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17325693 | METHOD FOR INDUCING HUMAN CHOLANGIOCYTE DIFFERENTIATION | May 2021 | October 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17316854 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF | May 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17188735 | Enzyme Granules | March 2021 | August 2025 | Abandon | 54 | 5 | 0 | Yes | No |
| 17166487 | ANTI-FIBRINOLYTIC LOADED PLATELETS | February 2021 | December 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17119511 | ADHERENT STROMAL CELLS DERIVED FROM PLACENTAS OF MULTIPLE DONORS AND USES THEREOF | December 2020 | September 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16972926 | CELL COMPOSITIONS AND USES THEREOF | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17104548 | PLATELET DIAGNOSTIC IMAGING AGENTS | November 2020 | July 2024 | Abandon | 44 | 2 | 1 | Yes | No |
| 17086308 | FOETAL POLYMIX OF MESENCHYMAL STEM CELLS UNDER HYPOXIC CONDITIONS FOR THE TREATMENT OF CLINICAL DISORDERS AND DISEASES | October 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17050734 | EXTRACELLULAR-MATRIX-CONTAINING COMPOSITION, TEMPORARY SCAFFOLD FOR THREE-DIMENSIONAL TISSUE FORMATION, THREE-DIMENSIONAL TISSUE FORMATION AGENT, AND METHOD FOR RECOVERING CELLS FROM THREE-DIMENSIONAL TISSUE | October 2020 | November 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 17074912 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | October 2020 | September 2024 | Allow | 47 | 5 | 1 | Yes | No |
| 17005674 | ASSEMBLOID - 3D MIMETIC TISSUE STRUCTURE BASED ON PATIENT- DERIVED MULTIPLE CELL TYPES AND METHOD OF MANUFACTURING THE SAME | August 2020 | March 2025 | Abandon | 55 | 5 | 1 | Yes | No |
| 17003845 | BREAST MILK DERIVED PROGENITOR CELLS AND CELL SYSTEMS | August 2020 | February 2026 | Abandon | 60 | 6 | 1 | Yes | No |
| 16976072 | METHOD FOR ISOLATING AND EXTRACTING ADIPOSE-DERIVED STEM CELLS FROM ADIPOSE TISSUE AND CULTURING SAME WITHOUT USING COLLAGENASE, AND KIT FOR ISOLATING AND EXTRACTING ADIPOSE-DERIVED STEM CELLS | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16994379 | MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS | August 2020 | December 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16985630 | METHOD FOR PRODUCING SHEET-SHAPED CELL CULTURE | August 2020 | August 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16916425 | LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION | June 2020 | April 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16907799 | Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In Bioreactors | June 2020 | January 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16762829 | PRODUCTION OF CANINE PANCREATIC ISLETS FROM AN IMMATURE PANCREAS | May 2020 | October 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16755650 | HOLLOW MICROCARRIER FOR SHEAR-FREE CULTURE OF ADHERENT CELLS IN BIOREACTORS | April 2020 | November 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16844382 | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response | April 2020 | May 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16834178 | PROTECTION OF THE VASCULAR ENDOTHELIUM FROM IMMUNOLOGICALLY MEDIATED CYTOTOXIC REACTIONS WITH HUMAN CD34-NEGATIVE PROGENITOR CELLS | March 2020 | April 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16648050 | HUMAN IN VITRO ORTHOTOPIC AND METASTATIC MODELS OF CANCER | March 2020 | October 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16818622 | CANINE BLOOD PLATELET PREPARATIONS | March 2020 | April 2024 | Abandon | 49 | 3 | 1 | No | No |
| 16642657 | METHOD FOR PRODUCING A THREE-DIMENSIONAL BIOLOGICAL STRUCTURE AND SAID STRUCTURE THUS OBTAINED | February 2020 | October 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16799592 | SEED TRAIN PROCESSES AND USES THEREOF | February 2020 | December 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16630799 | SURFACE-MODIFIED POLYMER SCAFFOLDS AND USES THEREOF | January 2020 | August 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16738495 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS | January 2020 | June 2024 | Abandon | 53 | 3 | 1 | No | Yes |
| 16627156 | METHOD FOR PRODUCING LAYERED CELL SHEET AND LAYERED CELL SHEET PRODUCED BY THE SAME | December 2019 | February 2023 | Allow | 37 | 2 | 0 | Yes | No |
| 16625501 | METHODS OF ISLET CELL CULTURE | December 2019 | November 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16708137 | IMAGING METHODS TO ASSESS THE EFFICACY OF ANTICANCER DRUGS IN VITRO USING SPONTANEOUSLY-FORMING SPHEROIDS | December 2019 | October 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16686158 | OMENTUM BASED SCAFFOLD AND DELIVERY SYSTEM | November 2019 | September 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16677735 | Manufacturing Method and Device for Three-Dimensional Engineered Tissue | November 2019 | January 2023 | Abandon | 39 | 2 | 1 | Yes | No |
| 16589220 | STEM CELLS AS AN INDIVIDUALIZED MATERNAL THERAPY FOR PREVENTION OF PREMATURITY | October 2019 | January 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 16580954 | CELL SPHEROIDS CONTAINING CAPILLARY STRUCTURES AND METHODS OF USING SAME | September 2019 | December 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16561721 | METHOD OF PREPARING MIMICKING ANGIOGENIC CO-SPHEROIDS AND APPLICATION THEREOF | September 2019 | January 2024 | Allow | 52 | 4 | 1 | No | No |
| 16482666 | COMPOSITIONS AND METHODS COMPRISING CO-CULTURE OF HEPATOCYTES | July 2019 | September 2025 | Abandon | 60 | 5 | 0 | No | Yes |
| 16517010 | REGULATING STEM CELLS | July 2019 | July 2023 | Abandon | 48 | 2 | 1 | No | No |
| 16502232 | HEPATOCYTE CONSTRUCT AND METHOD FOR PRODUCING THE SAME | July 2019 | December 2024 | Abandon | 60 | 5 | 1 | Yes | No |
| 16474895 | Methods for Generating Skeletal Muscle Progenitor Cells | June 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16386247 | MEDIA AND METHODS FOR EXPANSION OF PLURIPOTENT STEM CELLS | April 2019 | November 2022 | Abandon | 43 | 2 | 1 | Yes | No |
| 16382267 | METHODS FOR ISOLATING AND CULTURING LIVING CELLS USING METHOD OF PERMEABILIZING CELL MEMBRANE | April 2019 | August 2023 | Abandon | 52 | 2 | 1 | Yes | No |
| 16377020 | PHARMACEUTICAL COMPOSITION FOR TREATING DRUG-RESISTANT CANCER COMPRISING EXOSOMES DERIVED FROM DIFFERENTIATING STEM CELLS AS AN ACTIVE INGREDIENT | April 2019 | May 2023 | Abandon | 50 | 5 | 0 | Yes | No |
| 16339829 | COMPOSITION FOR PROMOTING GROWTH OF STEM CELLS COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVES THEREOF, AND COMPOSITION FOR CULTURING MEDIA OF STEM CELLS COMPRISING SAME | April 2019 | November 2024 | Abandon | 60 | 5 | 1 | Yes | No |
| 16374479 | METHODS AND COMPOSITIONS FOR PROVISION OF ANGIOGENIC FACTORS | April 2019 | March 2024 | Abandon | 60 | 4 | 0 | No | Yes |
| 16358443 | COMPOSITIONS COMPRISING CARDIOSPHERE-DERIVED CELLS | March 2019 | September 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16317456 | Innervated Artificial Intestine Compositions | January 2019 | May 2025 | Abandon | 60 | 2 | 1 | Yes | Yes |
| 16312062 | Three-Dimensional Tissue Matrix Scaffold System | December 2018 | February 2023 | Abandon | 50 | 4 | 1 | Yes | No |
| 16301494 | A CO-CULTURE SYSTEM AND METHOD FOR IN VITRO ASSESSMENT OF REVERSE CHOLESTEROL TRANSPORT | November 2018 | July 2023 | Allow | 57 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHUBERG, LAURA J.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHUBERG, LAURA J works in Art Unit 1631 and has examined 121 patent applications in our dataset. With an allowance rate of 33.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 53 months.
Examiner SCHUBERG, LAURA J's allowance rate of 33.1% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHUBERG, LAURA J receive 3.78 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SCHUBERG, LAURA J is 53 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.6% benefit to allowance rate for applications examined by SCHUBERG, LAURA J. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.3% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 14.8% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 112.0% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.